Compass Therapeutics, Inc.·4

Feb 18, 7:13 PM ET

Bisker-Leib Vered 4

4 · Compass Therapeutics, Inc. · Filed Feb 18, 2022

Insider Transaction Report

Form 4
Period: 2022-02-17
Bisker-Leib Vered
Chief Operating Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2022-02-17+500,000500,000 total
    Exercise: $2.52Exp: 2032-02-16Common Stock (500,000 underlying)
Footnotes (1)
  • [F1]The options vest over 48 substantially equal monthly installments starting 03/17/2022

Documents

1 file
  • 4
    ownership.xmlPrimary